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Abstract Although the majority of cancer cells are killed by
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand
treatment), certain types show resistance to it. Ionizing radiation
also induces cell death in cancer cells and may share common
intracellular pathways with TRAIL leading to apoptosis. In the
present study, we examined whether ionizing radiation could
overcome TRAIL resistance in the variant Jurkat clones. We
first selected TRAIL-resistant or -sensitive Jurkat clones and
examined cross-responsiveness of the clones between TRAIL and
radiation. Treatment with Q-radiation induced significant apo-
ptosis in all the clones, indicating that there seemed to be no
cross-resistance between TRAIL and radiation. Combined
treatment of radiation with TRAIL synergistically enhanced
killing of TRAIL-resistant cells, compared to TRAIL or
radiation alone. Apoptosis induced by combined treatment of
TRAIL and radiation in TRAIL-resistant cells was associated
with cleavage of caspase-8 and the proapoptotic Bid protein,
resulting in the activation of caspase-9 and caspase-3. No
changes in the expressions of TRAIL receptors (DR4 and DR5)
and Bcl-2 or Bax were found after treatment. The caspase
inhibitor z-VAD-fmk completely counteracted the synergistic
cell killing induced by combined treatment of TRAIL and
Q-radiation. These results demonstrated that ionizing radiation in
combination with TRAIL could overcome resistance to TRAIL
in TRAIL-resistant cells through TRAIL receptor-independent
synergistic activation of the cascades of the caspase-8 pathway,
suggesting a potential clinical application of combination
treatment of TRAIL and ionizing radiation to TRAIL-resistant
cancer cells. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Apoptosis of tumor cells can be initiated by triggering cell
death receptors, leading to activation of the intracellular ap-
optotic machinery. Chemotherapeutic drugs used in cancer
treatment may exert their therapeutic e¡ects by activating
these pathways. On the other hand, it is known that defects
in the apoptotic pathways or activation of antiapoptotic ma-
chineries can confer resistance to chemotherapy. Thus, control
of the balance between pro- and antiapoptotic processes with-
in the cell has been recognized as an important target for
therapeutic intervention [1,2].
Tumor necrosis factor (TNF)-related apoptosis-inducing li-
gand (TRAIL) is a member of the TNF family, which also
includes TNF, Fas ligand (FasL), and lymphotoxin-K. Pre-
vious studies suggest that unlike TNF and FasL, TRAIL is
capable of inducing apoptosis of various transformed or can-
cer cells but not of normal cells [3]. Because of this unique
ability, TRAIL may have a potential use in cancer treatment.
TRAIL can induce apoptosis by interacting with two recep-
tors: death receptor (DR) 4 (TRAIL-R1) and DR5 (TRAIL-
R2) [4^7]. TRAIL also binds two additional receptors, decoy
receptor (DcR) 1 (TRAIL-R3) and DcR2 (TRAIL-R4), which
are highly expressed in normal cells and believed to protect
apoptosis [6,8^10].
Apoptosis signal transduction and execution require the
coordinated action of the cascades of caspases, which are
aspartate-speci¢c cysteine proteases, and human caspases 1
through 11 have been described [11^13]. It has been shown
that caspase-8 and caspase-3 became activated when HeLa
cells were treated with TRAIL [14] and also caspase-3 cleav-
age was observed in TRAIL-sensitive breast cancer cells [15].
Therefore, although there is a missing link between TRAIL
DR and caspase activation, it is clear that TRAIL induces
apoptosis through the activation of caspases [5,6,8].
DNA damaging agents including etoposide and Q-radiation
often trigger the endogenous suicide machinery of cells, and
ionizing radiation-induced apoptosis requires activation of
multiple genes. In certain cancer cell types, radiation induces
apoptosis through the p53-directed de novo synthesis of the
death agonist Bax [16,17], indicating involvement of the mi-
tochondrial caspase pathway. However, it is still unclear how
the signal is transmitted to these enzymes. Recently, several
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reports demonstrated that DNA damaging chemotherapeutic
agents, such as doxorubicin, cisplatin or etoposide, and ion-
izing radiation enhanced TRAIL sensitivity in certain cancer
types [18^20]. However, con£icting results for the correlation
between apoptosis mediated by DNA damaging agents and by
TRAIL have been presented. Gibson et al. [21] and Gong et
al. [22] suggested that activation of TRAIL receptor was di-
rectly involved in etoposide- and radiation-mediated cell death
in certain cancer cells. On the other hand, Walczak et al. [23]
demonstrated that the pathway induced by etoposide was dis-
tinct from those induced by TRAIL. In the present study,
therefore, we examined whether TRAIL-resistant cancer cells
showed cross-resistance to Q-radiation and also whether com-
bination treatment of TRAIL and Q-radiation showed a syn-
ergistic cell killing e¡ect in TRAIL-resistant cancer cells. The
results obtained showed that TRAIL-resistant Jurkat clones
did not have cross-resistance to ionizing radiation and com-
bined treatment of radiation with TRAIL synergistically in-
creased cell death through the activation of the caspase path-
way in these clones resistant to TRAIL-induced apoptosis.
These results suggest that combined treatment of ionizing ra-
diation with TRAIL may be useful in the clinical treatment of
TRAIL-resistant human cancer.
2. Materials and methods
2.1. Cell culture
Jurkat human T cell lymphoma was obtained from the American
Type Culture Collection (Rockville, MD, USA). Cells were grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum, pen-
icillin and streptomycin.
2.2. Materials
Recombinant TRAIL was a gift from Dr. Byung-Ha Oh in POS-
TECH, South Korea. Polyclonal antibodies to caspase-8, caspase-3
and poly(ADP-ribose) polymerase (PARP) were purchased from Up-
state Biotechnology, and monoclonal antibodies to Bcl-2, Bax and Bid
were obtained from Santa Cruz Biotechnology.
2.3. Hoechst 33258 staining
Hoechst 33258 staining was performed as described previously [24].
Brie£y, cells were ¢xed with 4% paraformaldehyde for 30 min at room
temperature and washed once with phosphate-bu¡ered saline (PBS).
50 ng/ml Hoechst 33258 was added to the ¢xed cells, and they were
incubated for 30 min at room temperature and washed with PBS.
Cells were mounted and examined by £uorescence microscopy. Apo-
ptotic cells were identi¢ed by condensation and fragmentation of nu-
clei. The percentage of apoptotic cells was calculated as the ratio of
apoptotic cells to total cells countedU100. A minimum of 500 cells
was counted for each treatment.
2.4. Flow cytometric analysis
The expression of TRAIL-R1 (DR4) through TRAIL-R4 was
studied in the TRAIL-resistant cells by £ow cytometry. Cells were
incubated with appropriate concentrations of antibodies (diluted at
1:1000) for 1 h at room temperature, FITC-conjugated secondary
antibodies were added, after washing twice with PBS, and further
incubated for 1 h. Cells were then analyzed by FACScan £ow cyto-
metry (Becton Dickinson).
2.5. Western blot analysis
Western blot analysis was performed as described [25]. Brie£y, cell
lysates were prepared by extracting proteins with lysis bu¡er (40 mM
Tris^HCl, pH 8.0, 120 mM NaCl, 0.1% Nonidet-P40) supplemented
with protease inhibitors. Proteins were separated by SDS^PAGE and
transferred to nitrocellulose membrane. The membrane was blocked
with 5% non-fat dry milk in Tris-bu¡ered saline and then incubated
with primary antibodies for 1 h at room temperature. Blots were
developed by peroxidase-conjugated secondary antibody, and proteins
were visualized by enhanced chemiluminescence procedures (NEN)
according to the manufacturer’s recommendation.
3. Results and discussion
3.1. Selection of TRAIL-resistant and -sensitive Jurkat clones
Earlier reports demonstrated that normal cells were resis-
tant to TRAIL treatment, while cancer cells showed variable
responses to TRAIL: certain types of cancer cells showed re-
sistance to TRAIL [15,26^29], although the majority of cancer
cells were killed by TRAIL treatment. In this study, therefore,
we selected variant clones from parental Jurkat cells for sen-
sitivity or resistance to TRAIL-mediated apoptosis. As shown
in Fig. 1, clones TR3, TR4, TR5 and TR9 showed resistance
to TRAIL, whereas clone TR8 was relatively sensitive to
TRAIL, compared with parental Jurkat cells. When treated
with 100 ng/ml TRAIL, less than 15% of cells in the TRAIL-
resistant clones TR3, TR4, TR5 and TR9 showed apoptotic
morphology, as judged by Hoechst 33258 staining. However,
treatment of TRAIL-sensitive clone TR8 with 100 ng/ml of
recombinant TRAIL led to progressive apoptosis, over 60% of
the cells displaying apoptotic morphology within 24 h of
treatment.
3.2. TRAIL-resistant clones do not show cross-resistance
to Q-radiation
Recently, it has been demonstrated that CD95-resistant Jur-
kat clones show cross-resistance with ionizing radiation and
etoposide [30], suggesting that CD95 and DNA damaging
stimuli require common events to induce apoptosis. To deter-
mine whether TRAIL and ionizing radiation also have cross-
responsiveness in Jurkat clones, we examined the radiosensi-
tivity in TRAIL-sensitive and TRAIL-resistant clones (Fig. 2).
Treatment with 8 Gy Q-radiation caused signi¢cant apoptosis
of all the clones, indicating that these clones did not show
cross-sensitivity or -resistance to ionizing radiation. The fact
Fig. 1. Selection of TRAIL-resistant and -sensitive Jurkat clones.
Cells were treated with or without 100 ng/ml soluble human re-
combinant TRAIL and harvested after 24 h of incubation. Cells
were then ¢xed and stained with Hoechst 33258, and were examined
by £uorescence microscopy. Apoptotic cells were identi¢ed by con-
densed and fragmented nuclei. The data represent average values of
triplicate experiments with S.D.
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that TRAIL-resistant cells did not have cross-responsiveness
to ionizing radiation suggested potential circumvention of
TRAIL resistance by Q-radiation in certain cancer cells.
3.3. Ionizing radiation sensitizes TRAIL-resistant cells to
TRAIL-induced apoptosis
Earlier studies demonstrated that DNA damaging chemo-
therapeutic agents such as doxorubicin, cisplatin or etoposide
enhanced TRAIL sensitivity in certain cancer types [18^20],
therefore we next examined whether combined treatment of
radiation with TRAIL also had any synergistic e¡ect on ap-
optosis of TRAIL-resistant cells. As shown in Fig. 3, combi-
nation treatment indeed synergistically enhanced the killing of
all TRAIL-resistant cells. Similarly, Q-radiation also potenti-
ated the TRAIL e¡ect on parental Jurkat cells as well as
TRAIL-sensitive cells (data not shown). These ¢ndings sug-
gested that Q-radiation in combination with TRAIL modu-
lated the responsiveness to TRAIL from resistance to sensi-
tivity in TRAIL-resistant cells, resulting in synergistic
enhancement of the cell death.
3.4. Radiation in combination with TRAIL does not a¡ect
the expression of TRAIL receptors, Bcl-2 and Bax in
TRAIL-resistant cells
In certain cancer types, activation of TRAIL receptor is
directly involved in etoposide- and radiation-mediated cell
death [21,22]. In order to examine whether combined treat-
ment increased expression of TRAIL receptors (DR4 and
DR5) in TRAIL-resistant cells, we performed £ow cytometric
analysis with anti-DR4 and -DR5 antibodies. No comparable
changes were observed when TR9 cells were treated with ra-
diation or TRAIL alone or together (Fig. 4A). We also could
not observe any e¡ect on the expression of DcR1 and DcR2
by these treatments (data not shown). The transcriptional reg-
Fig. 2. TRAIL-resistant clones do not show cross-resistance to Q-radiation. Cells were treated with or without 8 Gy Q-radiation, and were har-
vested after 24 h. Then, cells were stained with Hoechst 33258, and apoptotic cells were identi¢ed by condensed and fragmented nuclei. The
data represent average values of triplicate experiments with S.D.
Fig. 3. Ionizing radiation sensitizes cells to the TRAIL-induced apoptosis in variant Jurkat clones. TRAIL-resistant Jurkat clones were treated
with 100 ng/ml recombinant TRAIL alone, 8 Gy radiation alone, or a combination of both for 24 h. Then, cells were stained with Hoechst
33258 and examined by £uorescence microscopy. Apoptotic cells were identi¢ed by condensed and fragmented nuclei. The data represent aver-
age values of triplicate experiments with S.D.
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ulation of Bcl-2 and Bax seems to be a key element of apo-
ptosis and to be related to mitochondria-mediated caspase
activation. In order to determine possible correlation existing
between enhancement of apoptosis by combination treatment
and Bcl-2 family expression, we performed Western blot anal-
ysis with antibodies against Bcl-2 and Bax proteins. As shown
in Fig. 4B, however, changes in Bcl-2 and Bax expression were
not observed in TRAIL-resistant clones after combined treat-
ment. One of the other molecules that possible interfere with
sensitivity to TRAIL is FLIP, FLICE-inhibitory protein. In
TRAIL-resistant cells, however, we did not observe any
changes in FLIP expression after treatment with TRAIL
and radiation alone or their combination (data not shown).
All of the above results suggested that the induction of apo-
ptosis by combined treatment of radiation and TRAIL was
TRAIL receptor-, Bcl-2- or Bax-independent.
3.5. Combination of radiation and TRAIL enhances cell death
by increasing caspase-8, Bid, caspase-9 and caspase-3
activation
The combined e¡ect of TRAIL and ionizing radiation on
cell killing in TRAIL-resistant clones suggested that proapo-
ptotic molecules were induced and they might reset the re-
sponsiveness of the cells from resistant to sensitive. To ¢nd
a possible convergence in apoptosis signaling by ionizing ra-
diation, we ¢rst tested whether ionizing radiation activated the
caspase pathway in TRAIL-resistant clones. Therefore we de-
termined which caspases were activated and their order of
activation by radiation through Western blot analysis of total
cell lysates with antibodies against initiator caspase-8, pro-
apoptotic Bid protein, caspase-9, and their e¡ector caspase-3
and its substrate PARP. As shown in Fig. 5, treatment of
clones TR5 and TR9 with TRAIL or radiation alone caused
only slight activation of caspase-8, -9 and -3. However, com-
bination treatment with radiation and TRAIL resulted in
much greater activation of caspase-8, Bid, caspase-9 and cas-
pase-3. Recently it has been demonstrated that DNA damag-
ing agents such as etoposide and doxorubicin can augment
TRAIL-induced apoptosis in breast cancer cells, perhaps by
inducing DR4 and/or DR5 expression and subsequent activa-
tion of caspase-8 and caspase-3 [15,21,26]. On the other hand,
con£icting results showing that the pathways induced by eto-
poside are distinct from those induced by TRAIL have also
been presented [23]. In this study, we observed that radiation-
mediated apoptosis was independent of the death receptors
DR4 and DR5, and therefore appeared to activate caspase-8
in a death receptor-independent fashion.
To clarify the role of caspase-8 and -3 activation in the
enhanced cell death by combination treatment, we examined
the e¡ect of a caspase inhibitor, benzyloxycarbonyl-Phe-Val-
Ala-Asp (Ome)-£uoromethylketone (z-VAD-fmk). Pretreat-
ment of clones TR5 and TR9 with z-VAD-fmk completely
blocked apoptosis induced by subsequent combined treatment
of Q-radiation with TRAIL as well as Q-radiation alone (data
Fig. 4. Radiation in combination with TRAIL does not a¡ect the expression of TRAIL receptors (DR4 and DR5), Bcl-2 and Bax in TRAIL-
resistant cells. A: TR9 cells were treated with 100 ng/ml recombinant TRAIL alone, 8 Gy radiation alone or a combination of both for 24 h.
Expression of DR4 and DR5 was examined by £ow cytometry after staining the cells with anti-DR4 and -DR5 antibody (diluted at 1:1000).
B: TR5 and TR9 cells were treated with 100 ng/ml recombinant TRAIL alone, 8 Gy radiation alone, or a combination of both for for the
times indicated. Cell lysates were prepared and Western blot analysis was performed using anti-Bcl-2 and -Bax antibodies. The data represent a
typical experiment conducted three times with similar results.
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not shown). These ¢ndings suggested that treatment with ra-
diation enhanced the TRAIL-mediated death-inducing signal-
ing complex without induction of TRAIL receptor expression,
which in turn caused enhanced activation of caspase-8 and
Bid, and resulted in the engagement of the mitochondrial
pathway in apoptosis.
In conclusion, in the present study, we have demonstrated
that ionizing radiation in combination with TRAIL can over-
come TRAIL resistance in selected Jurkat clones through the
TRAIL receptor-independent activation of the cascades of the
caspase-8 pathway. The results suggest that combined treat-
ment of TRAIL and ionizing radiation would be a promising
tool for the clinical therapy in TRAIL-resistant cancer cells.
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